Illumina (ILMN)
(Delayed Data from NSDQ)
$94.66 USD
-8.05 (-7.84%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $94.98 +0.32 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Illumina, Inc. has a PEG ratio of 2.05 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.85.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ILMN 94.66 -8.05(-7.84%)
Will ILMN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ILMN
Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
Gear Up for Illumina (ILMN) Q2 Earnings: Wall Street Estimates for Key Metrics
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Other News for ILMN
Cathie Wood's Ark Invest Loads Up On Coinbase, Roku, Illumina, And Bitmine Immersion
Decoding Illumina Inc (ILMN): A Strategic SWOT Insight
Illumina (ILMN) Surpasses Q2 Targets and Boosts 2025 Outlook
Illumina raises 2025 revenue and EPS guidance as clinical demand strengthens and multiomics acquisition advances
Illumina, Inc. 2025 Q2 - Results - Earnings Call Presentation